Levels of Matrix Metalloproteinase-1 and Tissue Inhibitors of Metalloproteinase-1 in Gastric Cancer

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2011 May 7

PMID 21547130

Citations 10

Authors

Ozgur Kemik

Ahu Sarbay Kemik

Aziz Sumer

Ahmet Cumhur Dulger

Mine Adas

Huseyin Begenik

Ismail Hasirci

Ozkan Yilmaz

Sevim Purisa

Erol Kisli

Sefa Tuzun

Cetin Kotan

Affiliations

Soon will be listed here.

Abstract

Aim: To evaluate the levels of preoperative serum matrix metalloproteinase-1 (MMP-1) and tissue inhibitor of metalloproteinase-1 (TIMP-1) in gastric cancer.

Methods: One hundred gastric cancer patients who underwent gastrectomy were enrolled in this study. The serum concentrations of MMP-1 and TIMP-1 in these patients and in fifty healthy controls were determined using an enzyme-linked immunosorbent assay.

Results: Higher serum MMP-1 and TIMP-1 levels were observed in patients than in controls (P < 0.001). Serum MMP-1 and TIMP-1 levels were positively associated with morphological appearance, tumor size, depth of wall invasion, lymph node metastasis, liver metastasis, perineural invasion, and pathological stage. They were not significantly associated with age, gender, tumor location, or histological type.

Conclusion: Increased MMP-1 and TIMP-1 were associated with gastric cancer. Although these markers are not good markers for diagnosis, these markers show in advanced gastric cancer.

Citing Articles

Coexpression of Matrix Metalloproteinase-7 and Tissue Inhibitor of Metalloproteinase-1 as a Prognostic Biomarker in Gastric Cancer.

Zhang Y, Qin L, Ma X, Wang Y, Wu Y, Jiang J Dis Markers. 2020; 2020:8831466.

PMID: 33005257 PMC: 7509560. DOI: 10.1155/2020/8831466.

Molecular markers associated with perineural invasion in pancreatic ductal adenocarcinoma.

Zhang J, Fu X, Liu D, Yang M, Yang J, Huo Y Oncol Lett. 2020; 20(4):5.

PMID: 32774479 PMC: 7405440. DOI: 10.3892/ol.2020.11866.

Serum Levels of Matrix Metalloproteinase-1 in Brazilian Patients with Benign Prostatic Hyperplasia or Prostate Cancer.

El-Chaer W, Cecilia Tonet-Furioso A, Santos Morais Junior G, Souza V, Avelar G, Henriques A Curr Gerontol Geriatr Res. 2020; 2020:6012102.

PMID: 32425999 PMC: 7222547. DOI: 10.1155/2020/6012102.

Molecular background of the regional lymph node metastasis of gastric cancer.

Zhu T, Hu X, Wei P, Shan G Oncol Lett. 2018; 15(3):3409-3414.

PMID: 29556271 PMC: 5844018. DOI: 10.3892/ol.2018.7813.

Tissue Inhibitor of Metalloproteinase-1 Is Confined to Tumor-Associated Myofibroblasts and Is Increased With Progression in Gastric Adenocarcinoma.

Alpizar-Alpizar W, Laerum O, Christensen I, Ovrebo K, Skarstein A, Hoyer-Hansen G J Histochem Cytochem. 2016; 64(8):483-94.

PMID: 27370797 PMC: 4971780. DOI: 10.1369/0022155416656173.

References

Curran S, Murray G . Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis. Eur J Cancer. 2000; 36(13 Spec No):1621-30. DOI: 10.1016/s0959-8049(00)00156-8. View

Hilska M, Roberts P, Collan Y, Laine V, Kossi J, Hirsimaki P . Prognostic significance of matrix metalloproteinases-1, -2, -7 and -13 and tissue inhibitors of metalloproteinases-1, -2, -3 and -4 in colorectal cancer. Int J Cancer. 2007; 121(4):714-23. DOI: 10.1002/ijc.22747. View

Karapanagiotidis G, Antonitsis P, Charokopos N, Foroulis C, Anastasiadis K, Rouska E . Serum levels of matrix metalloproteinases -1,-2,-3 and -9 in thoracic aortic diseases and acute myocardial ischemia. J Cardiothorac Surg. 2009; 4:59. PMC: 2774681. DOI: 10.1186/1749-8090-4-59. View

Brew K, Dinakarpandian D, Nagase H . Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta. 2000; 1477(1-2):267-83. DOI: 10.1016/s0167-4838(99)00279-4. View

Jiang Y, Goldberg I, Eric Shi Y . Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene. 2002; 21(14):2245-52. DOI: 10.1038/sj.onc.1205291. View

Boire A, Covic L, Agarwal A, Jacques S, Sherifi S, Kuliopulos A . PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell. 2005; 120(3):303-13. DOI: 10.1016/j.cell.2004.12.018. View

Ala-Aho R, Kahari V . Collagenases in cancer. Biochimie. 2005; 87(3-4):273-86. DOI: 10.1016/j.biochi.2004.12.009. View

Sunami E, Tsuno N, Osada T, Saito S, Kitayama J, Tomozawa S . MMP-1 is a prognostic marker for hematogenous metastasis of colorectal cancer. Oncologist. 2000; 5(2):108-14. DOI: 10.1634/theoncologist.5-2-108. View

Shiozawa J, Ito M, Nakayama T, Nakashima M, Kohno S, Sekine I . Expression of matrix metalloproteinase-1 in human colorectal carcinoma. Mod Pathol. 2000; 13(9):925-33. DOI: 10.1038/modpathol.3880169. View

10.

Brennan F, Browne K, Green P, Jaspar J, Maini R, Feldmann M . Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-alpha (cA2) therapy. Br J Rheumatol. 1997; 36(6):643-50. DOI: 10.1093/rheumatology/36.6.643. View

11.

Nomura H, Fujimoto N, Seiki M, Mai M, Okada Y . Enhanced production of matrix metalloproteinases and activation of matrix metalloproteinase 2 (gelatinase A) in human gastric carcinomas. Int J Cancer. 1996; 69(1):9-16. DOI: 10.1002/(SICI)1097-0215(19960220)69:1<9::AID-IJC3>3.0.CO;2-8. View

12.

Papazoglou D, Papatheodorou K, Papanas N, Papadopoulos T, Gioka T, Kabouromiti G . Matrix metalloproteinase-1 and tissue inhibitor of metalloproteinases-1 levels in severely obese patients: what is the effect of weight loss?. Exp Clin Endocrinol Diabetes. 2010; 118(10):730-4. DOI: 10.1055/s-0030-1249671. View

13.

Sutnar A, Pesta M, Liska V, Treska V, Skalicky T, Kormunda S . Clinical relevance of the expression of mRNA of MMP-7, MMP-9, TIMP-1, TIMP-2 and CEA tissue samples from colorectal liver metastases. Tumour Biol. 2007; 28(5):247-52. DOI: 10.1159/000110897. View

14.

Muzzillo D, Imoto M, Fukuda Y, Koyama Y, Saga S, Nagai Y . Clinical evaluation of serum tissue inhibitor of metalloproteinases-1 levels in patients with liver diseases. J Gastroenterol Hepatol. 1993; 8(5):437-41. DOI: 10.1111/j.1440-1746.1993.tb01544.x. View

15.

Wang C, Wu T, Tsao K, Sun C . Serum TIMP-1 in gastric cancer patients: a potential prognostic biomarker. Ann Clin Lab Sci. 2006; 36(1):23-30. View

16.

Manenti L, Paganoni P, Floriani I, Landoni F, Torri V, Buda A . Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma. Eur J Cancer. 2003; 39(13):1948-56. DOI: 10.1016/s0959-8049(03)00427-1. View

17.

Mori M, Mimori K, Sadanaga N, Inoue H, Tanaka Y, Mafune K . Prognostic impact of tissue inhibitor of matrix metalloproteinase-1 in esophageal carcinoma. Int J Cancer. 2000; 88(4):575-8. DOI: 10.1002/1097-0215(20001115)88:4<575::aid-ijc9>3.0.co;2-c. View

18.

Nagase H, Barrett A, Woessner Jr J . Nomenclature and glossary of the matrix metalloproteinases. Matrix Suppl. 1992; 1:421-4. View

19.

Baker T, Tickle S, Wasan H, Docherty A, Isenberg D, Waxman J . Serum metalloproteinases and their inhibitors: markers for malignant potential. Br J Cancer. 1994; 70(3):506-12. PMC: 2033376. DOI: 10.1038/bjc.1994.336. View

20.

Nagase H, Woessner Jr J . Matrix metalloproteinases. J Biol Chem. 1999; 274(31):21491-4. DOI: 10.1074/jbc.274.31.21491. View